Vaccines Almost Eliminated HPV 16 & 18
Vaccination against human papillomavirus (HPV) has been introduced as a public health initiative in many countries, including Denmark since October 2008.
A recent study in Demark of HPV-prevalence in women found very positive cancer-prevention results.
At age 23-24 years, HPV 16 and 18 were almost eliminated, where 92 percent of young women had accepted HPV-vaccination offered at the age of 14 years.
In the period from February 2017 - April 2019, 6,233 screening samples from women born in 1994 were selected for HPV-analysis; 27 samples had no HPV-test and 3 samples had no HPV-diagnosis, leaving 6203 samples with an HPV-diagnosis.
Prevalence of any high-risk (HR) HPV was 35 percent; only 0.9 percent were positive for vaccine HPV-types 16/18, while the remaining 34 percent were positive for other HR HPV.
When comparing with pre-vaccination prevalence data, HPV-16/18 decreased by 95%; RR=0.05 (95% CI 0.04-0.06), while other HR HPV remained fairly constant.
And, one-third of women vaccinated as girls with the quadrivalent HPV-vaccine were HR HPV-positive at the time of the first invitation to screening.
All three HPV-vaccines protect against the high-risk (HR) types 16 and 18, accounting for 70 percent of cervical cancers.
The 9-valent HPV-vaccine protects against an additional five HR HPV-types (31,33, 45,52 and 58), and is expected to prevent 90 percent of cervical cancers.
Vax-Before-Cancer publishes HPV vaccination news.